Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 2000

View Archived Issues

Stem cell transplant benefits some renal cell carcinoma patients

Cell growth switch enhances stem cell gene therapy

Celecoxib associated with fewer adverse effects than NSAIDs, according to CLASS

LY-339624: a new subtype-selective kainate receptor agonist

Preclinical results in guinea pigs suggest novel mechanism of action for TAK-637

Novel RSV fusion inhibitor shows potential for prophylactic and therapeutic treatment

Inspire and Kirin enter lung diagnostic collaboration for Asia

Combination of doxazosin and amlodipine provides increased efficacy, improved tolerability

Cardioprotective agents from Pierre Fabre evaluated in several animal models

Derivatives of 4-demethylpenclomedine useful as antitumor agents

U. of Toledo describes new class of muscarinic receptor agonists

Synthesis and use of heterocyclic neurotrophic agents reported by NeuroSearch

Kirin Brewery investigates antitumor activity of quinoline and quinazoline derivatives

Vasodilating and antiplatelet series designed at Lacer

Novel 5-HT2 receptor ligands described by Vernalis for use particularly in obesity

Preparation and therapeutic use of new neurotrophic agents described in recent patent

Caspofungin, a water-soluble echinocandin antifungal, highlighted at ICAAC this week

Japanese lab identifies benzimidazole-based antitumor agents

Scotia updates development projects for first half 2000

Long-term therapy with entecavir assessed in woodchuck model of chronic HBV infection

Deltagen and Glaxo Wellcome enter genetics agreements

Aurora Biosciences announces therapeutic drug discovery alliance

Atrisorb barrier with doxycycline approved by FDA

Zonagen's product for FSD shows promise in clinical trial

Immtech International receives SBIR grant for DB-289

Complement inhibitor TP-10 to enter phase IIb studies in infants

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...